Skip NavigationSkip to Content

Therapeutic Vulnerability of an In Vivo Model of Alveolar Soft Part Sarcoma (ASPS) to Antiangiogenic Therapy

  1. Author:
    Vistica, D. T.
    Hollingshead, M.
    Borgel, S. D.
    Kenney, S.
    Stockwin, L. H.
    Raffeld, M.
    Schrump, D. S.
    Burkett, S.
    Stone, G.
    Butcher, D. O.
    Shoemaker, R. H.
  2. Author Address

    Vistica, David T.] NCI, Screening Technol Branch, Dev Therapeut Program, Frederick, MD 21702 USA. [Hollingshead, Melinda] NCI, Biol Testing Branch, Frederick, MD 21702 USA. [Borgel, Suzanne D.; Stockwin, Luke H.] NCI, Dev Therapeut Program, SAIC Frederick, Frederick, MD 21702 USA. [Burkett, Sandra, Stone, Gary] NCI, Comparat Mol Cytogenet Core Facil, Ctr Canc Res, Frederick, MD 21702 USA. [Butcher, Donna O.] NCI, Pathol Histotechnol Lab, SAIC Frederick Inc, Frederick, MD 21702 USA. [Raffeld, Mark] NCI, Pathol Lab, Ctr Canc Res, Frederick, MD 21702 USA. [Schrump, David S.] NCI, Thorac Oncol Sect, Surg Branch, Ctr Canc Res, Frederick, MD 21702 USA.
    1. Year: 2009
  1. Journal: Journal of Pediatric Hematology Oncology
    1. 31
    2. 8
    3. Pages: 561-570
  2. Type of Article: Article
  1. Abstract:

    In vivo growth of alveolar soft part sarcoma (ASPS) was achieved using subcutaneous xenografts in sex-matched nonobese diabetic severe combined immunodeficiency mice. One tumor, currently at passage 6, has been maintained in vivo for 32 months and has maintained characteristics consistent with those of the original ASPS tumor including (1) tumor histology and staining with periodic acid Schiff/diastase, (2) the presence of the ASPL-TFE3 type I fusion transcript, (3) nuclear staining with antibodies to the ASPL-TFE3 type I fusion protein, (4) maintenance of the t(X,17)(p11,q25) translocation characteristic of ASPS, (5) stable expression of signature ASPS gene transcripts and finally, the development and maintenance of a functional vascular network, a hallmark of ASPS. The ASPS xenograft tumor vasculature encompassing nests of ASPS cells is highly reactive to antibodies against the endothelial antigen CD34 and is readily accessible to intravenously administered fluorescein isothiocyanate-dextran. The therapeutic vulnerability of this tumor model to antiangiogenic therapy, targeting vascular endothelial growth factor and hypoxia-inducible factor-1 alpha, was examined using bevacizumab and topotecan alone and in combination. Together, the 2 drugs produced a 70% growth delay accompanied by a 0.7 net log cell kill that was superior to the antitumor effect produced by either drug alone. In summary, this Study describes a preclinical in vivo model for ASPS which will facilitate investigation into the biology of this slow growing soft tissue sarcoma and demonstrates the feasibility of using an antiangiogenic approach in the treatment of ASPS.

    See More

External Sources

  1. PMID: 19636271

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel